You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameVindesine
Accession NumberDB00309  (APRD00392)
TypeSmall Molecule
GroupsApproved
DescriptionVinblastine derivative with antineoplastic activity against cancer. Major side effects are myelosuppression and neurotoxicity. Vindesine is used extensively in chemotherapy protocols (antineoplastic combined chemotherapy protocols). [PubChem]
Structure
Thumb
Synonyms
3-(Aminocarbonyl)-O(4)-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine
3-Carbamoyl-4-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine
Desacetylvinblastine amide
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Eldisine Inj 5mg/2mlPowder, for solution5 mgIntravenousEli Lilly Canada Inc1982-12-312000-08-03Canada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
EldesineNot Available
EldisineNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Vindesine Sulfate
59917-39-4
Thumb
  • InChI Key: COFJBSXICYYSKG-FJFFLIEUSA-N
  • Monoisotopic Mass: 851.377528381
  • Average Mass: 852.005
DBSALT000440
Categories
UNIIRSA8KO39WH
CAS number53643-48-4
WeightAverage: 753.9261
Monoisotopic: 753.410149139
Chemical FormulaC43H55N5O7
InChI KeyHHJUWIANJFBDHT-KOTLKJBCSA-N
InChI
InChI=1S/C43H55N5O7/c1-6-39(52)21-25-22-42(38(51)55-5,33-27(13-17-47(23-25)24-39)26-11-8-9-12-30(26)45-33)29-19-28-31(20-32(29)54-4)46(3)35-41(28)15-18-48-16-10-14-40(7-2,34(41)48)36(49)43(35,53)37(44)50/h8-12,14,19-20,25,34-36,45,49,52-53H,6-7,13,15-18,21-24H2,1-5H3,(H2,44,50)/t25-,34+,35-,36-,39+,40-,41-,42+,43+/m1/s1
IUPAC Name
methyl (13S,15S,17S)-13-[(1R,9R,10S,11R,12R,19R)-10-carbamoyl-12-ethyl-10,11-dihydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.0¹,⁹.0²,⁷.0¹⁶,¹⁹]nonadeca-2,4,6,13-tetraen-4-yl]-17-ethyl-17-hydroxy-1,11-diazatetracyclo[13.3.1.0⁴,¹².0⁵,¹⁰]nonadeca-4(12),5,7,9-tetraene-13-carboxylate
SMILES
[H][C@@]12N3CC[C@@]11C4=CC(=C(OC)C=C4N(C)[C@@]1([H])[C@](O)([[email protected]](O)[C@]2(CC)C=CC3)C(N)=O)[C@]1(C[C@]2([H])CN(C[C@](O)(CC)C2)CCC2=C1NC1=CC=CC=C21)C(=O)OC
Pharmacology
IndicationFor the treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia and acute panmyelosis
Structured Indications Not Available
PharmacodynamicsVindesine is indicated for the treatment of acute lymphocytic leukemia of childhood that is resistant to vincristine and non-oat cell lung cancer.Vindesine causes the arrest of cells in metaphase mitosis. It is three times more potent than vincristine and nearly 10 times more potent than vinblastine in causing mitotic arrest in in vitro studies at doses designed to arrest from 10 to 15% of the cells in mitosis. Vindesine and vincristine are approximately equipotent at dose levels that arrest 40 to 50% of the cells in mitosis. Unlike vinblastine, vindesine produces very few postmetaphase cells. Vindesine has demonstrated activity in patients who have relapsed while receiving multiple-agent treatment that included vincristine.
Mechanism of actionVindesine acts by causing the arrest of cells in metaphase mitosis through its inhibition tubulin mitotic funcitoning. The drug is cell-cycle specific for the S phase.
TargetKindPharmacological actionActionsOrganismUniProt ID
Tubulin beta-1 chainProteinyes
inhibitor
HumanQ9H4B7 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein binding65-75%
Metabolism

Hepatic

SubstrateEnzymesProduct
Vindesine
UnknownDetails
Route of eliminationNot Available
Half life24 hours.
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Vindesine Action PathwayDrug actionSMP00438
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Vindesine.Approved
ALT-110The risk or severity of adverse effects can be increased when Vindesine is combined with ALT-110.Investigational
AmiodaroneThe serum concentration of Vindesine can be increased when it is combined with Amiodarone.Approved, Investigational
AnvirzelAnvirzel may decrease the cardiotoxic activities of Vindesine.Investigational
AprepitantThe serum concentration of Vindesine can be increased when it is combined with Aprepitant.Approved, Investigational
AtazanavirThe serum concentration of Vindesine can be increased when it is combined with Atazanavir.Approved, Investigational
AtomoxetineThe serum concentration of Vindesine can be increased when it is combined with Atomoxetine.Approved
BcgThe therapeutic efficacy of Bcg can be decreased when used in combination with Vindesine.Investigational
BevacizumabBevacizumab may increase the cardiotoxic activities of Vindesine.Approved, Investigational
BexaroteneThe serum concentration of Vindesine can be decreased when it is combined with Bexarotene.Approved, Investigational
BoceprevirThe serum concentration of Vindesine can be increased when it is combined with Boceprevir.Approved
BortezomibThe serum concentration of Vindesine can be increased when it is combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Vindesine can be decreased when it is combined with Bosentan.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Vindesine.Approved
CarbamazepineThe metabolism of Vindesine can be increased when combined with Carbamazepine.Approved, Investigational
CarbomycinThe serum concentration of Vindesine can be increased when it is combined with Carbomycin.Vet Approved
CDX-110The risk or severity of adverse effects can be increased when Vindesine is combined with CDX-110.Investigational
CeritinibThe serum concentration of Vindesine can be increased when it is combined with Ceritinib.Approved
ClarithromycinThe serum concentration of Vindesine can be increased when it is combined with Clarithromycin.Approved
ClemastineThe serum concentration of Vindesine can be increased when it is combined with Clemastine.Approved
ClotrimazoleThe serum concentration of Vindesine can be increased when it is combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Vindesine is combined with Clozapine.Approved
CobicistatThe serum concentration of Vindesine can be increased when it is combined with Cobicistat.Approved
ConivaptanThe serum concentration of Vindesine can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe serum concentration of Vindesine can be increased when it is combined with Crizotinib.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Vindesine.Approved, Investigational
CyclosporineThe serum concentration of Vindesine can be increased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
DabrafenibThe serum concentration of Vindesine can be decreased when it is combined with Dabrafenib.Approved
DarunavirThe serum concentration of Vindesine can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Vindesine can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Vindesine can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe serum concentration of Vindesine can be increased when it is combined with Delavirdine.Approved
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Vindesine.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Vindesine.Approved
DexamethasoneThe serum concentration of Vindesine can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Vindesine.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Vindesine.Approved
DihydroergotamineThe serum concentration of Vindesine can be increased when it is combined with Dihydroergotamine.Approved
DiltiazemThe serum concentration of Vindesine can be increased when it is combined with Diltiazem.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Vindesine.Approved, Investigational
DoxycyclineThe serum concentration of Vindesine can be increased when it is combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe serum concentration of Vindesine can be increased when it is combined with Dronedarone.Approved
EfavirenzThe serum concentration of Vindesine can be decreased when it is combined with Efavirenz.Approved, Investigational
EnzalutamideThe serum concentration of Vindesine can be decreased when it is combined with Enzalutamide.Approved
ErythromycinThe serum concentration of Vindesine can be increased when it is combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Vindesine can be decreased when it is combined with Eslicarbazepine acetate.Approved
EtravirineThe serum concentration of Vindesine can be decreased when it is combined with Etravirine.Approved
FingolimodVindesine may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FluconazoleThe serum concentration of Vindesine can be increased when it is combined with Fluconazole.Approved
FluvoxamineThe serum concentration of Vindesine can be increased when it is combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe serum concentration of Vindesine can be increased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Vindesine can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Vindesine can be increased when combined with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Vindesine can be increased when it is combined with Fusidic Acid.Approved
G17DTThe risk or severity of adverse effects can be increased when Vindesine is combined with G17DT.Investigational
GI-5005The risk or severity of adverse effects can be increased when Vindesine is combined with GI-5005.Investigational
IdelalisibThe serum concentration of Vindesine can be increased when it is combined with Idelalisib.Approved
ImatinibThe serum concentration of Vindesine can be increased when it is combined with Imatinib.Approved
IndinavirThe serum concentration of Vindesine can be increased when it is combined with Indinavir.Approved
INGN 201The risk or severity of adverse effects can be increased when Vindesine is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Vindesine is combined with INGN 225.Investigational
IsavuconazoniumThe serum concentration of Vindesine can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsradipineThe serum concentration of Vindesine can be increased when it is combined with Isradipine.Approved
ItraconazoleThe serum concentration of Vindesine can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Vindesine can be increased when it is combined with Ivacaftor.Approved
JosamycinThe serum concentration of Vindesine can be increased when it is combined with Josamycin.Approved
KetoconazoleThe serum concentration of Vindesine can be increased when it is combined with Ketoconazole.Approved, Investigational
KitasamycinThe serum concentration of Vindesine can be increased when it is combined with Kitasamycin.Experimental
LeflunomideThe risk or severity of adverse effects can be increased when Vindesine is combined with Leflunomide.Approved, Investigational
LopinavirThe serum concentration of Vindesine can be increased when it is combined with Lopinavir.Approved
LovastatinThe serum concentration of Vindesine can be increased when it is combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Vindesine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Vindesine can be increased when combined with Lumacaftor.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Vindesine.Withdrawn
MifepristoneThe serum concentration of Vindesine can be increased when it is combined with Mifepristone.Approved, Investigational
MitomycinThe risk or severity of adverse effects can be increased when Vindesine is combined with Mitomycin.Approved
MitotaneThe serum concentration of Vindesine can be decreased when it is combined with Mitotane.Approved
ModafinilThe serum concentration of Vindesine can be decreased when it is combined with Modafinil.Approved, Investigational
NafcillinThe serum concentration of Vindesine can be decreased when it is combined with Nafcillin.Approved
NatalizumabThe risk or severity of adverse effects can be increased when Vindesine is combined with Natalizumab.Approved, Investigational
NefazodoneThe serum concentration of Vindesine can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Vindesine can be increased when it is combined with Nelfinavir.Approved
NetupitantThe serum concentration of Vindesine can be increased when it is combined with Netupitant.Approved
NevirapineThe serum concentration of Vindesine can be increased when it is combined with Nevirapine.Approved
NilotinibThe serum concentration of Vindesine can be increased when it is combined with Nilotinib.Approved, Investigational
OlaparibThe serum concentration of Vindesine can be increased when it is combined with Olaparib.Approved
OleandomycinThe serum concentration of Vindesine can be increased when it is combined with Oleandomycin.Vet Approved
OsimertinibThe serum concentration of Vindesine can be increased when it is combined with Osimertinib.Approved
OuabainOuabain may decrease the cardiotoxic activities of Vindesine.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Vindesine.Approved, Vet Approved
PalbociclibThe serum concentration of Vindesine can be increased when it is combined with Palbociclib.Approved
PentobarbitalThe metabolism of Vindesine can be increased when combined with Pentobarbital.Approved, Vet Approved
PhenobarbitalThe metabolism of Vindesine can be increased when combined with Phenobarbital.Approved
PhenytoinThe serum concentration of Phenytoin can be decreased when it is combined with Vindesine.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Vindesine.Approved, Investigational
PosaconazoleThe risk or severity of adverse effects can be increased when Posaconazole is combined with Vindesine.Approved, Investigational, Vet Approved
PrimidoneThe metabolism of Vindesine can be increased when combined with Primidone.Approved, Vet Approved
Rabies vaccineThe risk or severity of adverse effects can be increased when Vindesine is combined with Rabies vaccine.Approved
Rabies vaccineThe therapeutic efficacy of Rabies vaccine can be decreased when used in combination with Vindesine.Approved
RanolazineThe serum concentration of Vindesine can be increased when it is combined with Ranolazine.Approved, Investigational
RifabutinThe metabolism of Vindesine can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Vindesine can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Vindesine can be increased when combined with Rifapentine.Approved
RitonavirThe serum concentration of Vindesine can be increased when it is combined with Ritonavir.Approved, Investigational
RoflumilastRoflumilast may increase the immunosuppressive activities of Vindesine.Approved
SaquinavirThe serum concentration of Vindesine can be increased when it is combined with Saquinavir.Approved, Investigational
SildenafilThe serum concentration of Vindesine can be increased when it is combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Vindesine can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Vindesine can be increased when it is combined with Simeprevir.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Vindesine.Approved
SolithromycinThe serum concentration of Vindesine can be increased when it is combined with Solithromycin.Investigational
SpiramycinThe serum concentration of Vindesine can be increased when it is combined with Spiramycin.Approved
SRP 299The risk or severity of adverse effects can be increased when Vindesine is combined with SRP 299.Investigational
St. John's WortThe serum concentration of Vindesine can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Vindesine can be increased when it is combined with Stiripentol.Approved
SulfisoxazoleThe serum concentration of Vindesine can be increased when it is combined with Sulfisoxazole.Approved, Vet Approved
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Vindesine.Approved, Investigational
TelaprevirThe serum concentration of Vindesine can be increased when it is combined with Telaprevir.Approved
TelithromycinThe serum concentration of Vindesine can be increased when it is combined with Telithromycin.Approved
TG4010The risk or severity of adverse effects can be increased when Vindesine is combined with TG4010.Investigational
TiclopidineThe serum concentration of Vindesine can be increased when it is combined with Ticlopidine.Approved
TocilizumabThe serum concentration of Vindesine can be decreased when it is combined with Tocilizumab.Approved
TofacitinibVindesine may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Vindesine.Approved, Investigational
TroleandomycinThe serum concentration of Vindesine can be increased when it is combined with Troleandomycin.Approved
TylosinThe serum concentration of Vindesine can be increased when it is combined with Tylosin.Vet Approved
VenlafaxineThe serum concentration of Vindesine can be increased when it is combined with Venlafaxine.Approved
VerapamilThe serum concentration of Vindesine can be increased when it is combined with Verapamil.Approved
VoriconazoleThe risk or severity of adverse effects can be increased when Voriconazole is combined with Vindesine.Approved, Investigational
ZiprasidoneThe serum concentration of Vindesine can be increased when it is combined with Ziprasidone.Approved
Food InteractionsNot Available
References
Synthesis Reference

Stanislaw Rolski, “Method of preparing vindesine sulfate.” U.S. Patent US4259242, issued September, 1965.

US4259242
General ReferencesNot Available
External Links
ATC CodesL01CA03
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9027
Blood Brain Barrier-0.9821
Caco-2 permeable-0.5154
P-glycoprotein substrateSubstrate0.9164
P-glycoprotein inhibitor INon-inhibitor0.5717
P-glycoprotein inhibitor IINon-inhibitor0.6577
Renal organic cation transporterNon-inhibitor0.8851
CYP450 2C9 substrateNon-substrate0.8468
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.7597
CYP450 1A2 substrateNon-inhibitor0.8766
CYP450 2C9 inhibitorNon-inhibitor0.8798
CYP450 2D6 inhibitorNon-inhibitor0.8911
CYP450 2C19 inhibitorNon-inhibitor0.8814
CYP450 3A4 inhibitorNon-inhibitor0.811
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.933
Ames testNon AMES toxic0.8682
CarcinogenicityNon-carcinogens0.8976
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.9430 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9892
hERG inhibition (predictor II)Inhibitor0.6584
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Powder, for solutionIntravenous5 mg
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point230-232 °CNot Available
logP2.9Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.07 mg/mLALOGPS
logP3.53ALOGPS
logP2.79ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)11.34ChemAxon
pKa (Strongest Basic)8.68ChemAxon
Physiological Charge2ChemAxon
Hydrogen Acceptor Count9ChemAxon
Hydrogen Donor Count5ChemAxon
Polar Surface Area164.82 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity210.32 m3·mol-1ChemAxon
Polarizability82.58 Å3ChemAxon
Number of Rings9ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as vinca alkaloids. These are alkaloids with a dimeric chemical structure composed of an indole nucleus (catharanthine), and a dihydroindole nucleus (vindoline), joined together.
KingdomOrganic compounds
Super ClassAlkaloids and derivatives
ClassVinca alkaloids
Sub ClassNot Available
Direct ParentVinca alkaloids
Alternative Parents
Substituents
  • Vinca alkaloid skeleton
  • Quinoline-6-carboxamide
  • Carbazole
  • Indole or derivatives
  • Indole
  • Dialkylarylamine
  • Anisole
  • Aralkylamine
  • Tetrahydropyridine
  • Alkyl aryl ether
  • Benzenoid
  • N-alkylpyrrolidine
  • Piperidine
  • Heteroaromatic compound
  • Methyl ester
  • Tertiary alcohol
  • Pyrrolidine
  • Pyrrole
  • Cyclic alcohol
  • Tertiary aliphatic amine
  • Tertiary amine
  • Secondary alcohol
  • Primary carboxylic acid amide
  • Carboxylic acid ester
  • Carboxamide group
  • 1,2-diol
  • 1,2-aminoalcohol
  • Azacycle
  • Organoheterocyclic compound
  • Monocarboxylic acid or derivatives
  • Ether
  • Carboxylic acid derivative
  • Carboxylic acid amide
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Alcohol
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Structural constituent of cytoskeleton
Specific Function:
Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha chain (By similarity).
Gene Name:
TUBB1
Uniprot ID:
Q9H4B7
Molecular Weight:
50326.56 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Natsume T, Watanabe J, Tamaoki S, Fujio N, Miyasaka K, Kobayashi M: Characterization of the interaction of TZT-1027, a potent antitumor agent, with tubulin. Jpn J Cancer Res. 2000 Jul;91(7):737-47. [PubMed:10920282 ]
  4. Yoshida M, Matsui Y, Ikarashi Y, Usui T, Osada H, Wakasugi H: Antiproliferating activity of the mitotic inhibitor pironetin against vindesine- and paclitaxel-resistant human small cell lung cancer H69 cells. Anticancer Res. 2007 Mar-Apr;27(2):729-36. [PubMed:17465195 ]
  5. Fiebig HH, Schuler J, Bausch N, Hofmann M, Metz T, Korrat A: Gene signatures developed from patient tumor explants grown in nude mice to predict tumor response to 11 cytotoxic drugs. Cancer Genomics Proteomics. 2007 May-Jun;4(3):197-209. [PubMed:17878523 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Ekins S, Bravi G, Wikel JH, Wrighton SA: Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. J Pharmacol Exp Ther. 1999 Oct;291(1):424-33. [PubMed:10490933 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23